Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).

Debelle F, Meeus G, Dratwa M, Maes B, Vanholder R, Albert A, Schutyser E, Jadoul M.

Acta Clin Belg. 2013 Jul-Aug;68(4):275-81.


Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer.

Verbeke H, De Hertogh G, Li S, Vandercappellen J, Noppen S, Schutyser E, El-Asrar AA, Opdenakker G, Van Damme J, Geboes K, Struyf S.

Hum Pathol. 2010 Jul;41(7):990-1001. doi: 10.1016/j.humpath.2009.09.021. Epub 2010 Mar 23.


Carcinoma cell-derived chemokines and their presence in oral fluid.

Michiels K, Schutyser E, Conings R, Lenaerts JP, Put W, Nuyts S, Delaere P, Jacobs R, Struyf S, Proost P, Van Damme J.

Eur J Oral Sci. 2009 Aug;117(4):362-8. doi: 10.1111/j.1600-0722.2009.00644.x.


Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation.

Proost P, Loos T, Mortier A, Schutyser E, Gouwy M, Noppen S, Dillen C, Ronsse I, Conings R, Struyf S, Opdenakker G, Maudgal PC, Van Damme J.

J Exp Med. 2008 Sep 1;205(9):2085-97. doi: 10.1084/jem.20080305. Epub 2008 Aug 18.


Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events.

Gouwy M, Struyf S, Noppen S, Schutyser E, Springael JY, Parmentier M, Proost P, Van Damme J.

Mol Pharmacol. 2008 Aug;74(2):485-95. doi: 10.1124/mol.108.045146. Epub 2008 May 9.


Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells.

Vandercappellen J, Noppen S, Verbeke H, Put W, Conings R, Gouwy M, Schutyser E, Proost P, Sciot R, Geboes K, Opdenakker G, Van Damme J, Struyf S.

J Leukoc Biol. 2007 Dec;82(6):1519-30. Epub 2007 Sep 7.


Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells.

Schutyser E, Su Y, Yu Y, Gouwy M, Zaja-Milatovic S, Van Damme J, Richmond A.

Eur Cytokine Netw. 2007 Jun;18(2):59-70. Epub 2007 Jun 26.


Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration.

Proost P, Mortier A, Loos T, Vandercappellen J, Gouwy M, Ronsse I, Schutyser E, Put W, Parmentier M, Struyf S, Van Damme J.

Blood. 2007 Jul 1;110(1):37-44. Epub 2007 Mar 15.


TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis.

Loos T, Dekeyzer L, Struyf S, Schutyser E, Gijsbers K, Gouwy M, Fraeyman A, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J, Proost P.

Lab Invest. 2006 Sep;86(9):902-16. Epub 2006 Jul 17.


Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies.

Proost P, Struyf S, Loos T, Gouwy M, Schutyser E, Conings R, Ronsse I, Parmentier M, Grillet B, Opdenakker G, Balzarini J, Van Damme J.

Arthritis Res Ther. 2006;8(4):R107.


Chemokine receptor internalization and intracellular trafficking.

Neel NF, Schutyser E, Sai J, Fan GH, Richmond A.

Cytokine Growth Factor Rev. 2005 Dec;16(6):637-58. Epub 2005 Jul 5. Review.


Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes.

Schutyser E, Richmond A, Van Damme J.

J Leukoc Biol. 2005 Jul;78(1):14-26. Epub 2005 Mar 22. Review.


Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.

Proost P, Verpoest S, Van de Borne K, Schutyser E, Struyf S, Put W, Ronsse I, Grillet B, Opdenakker G, Van Damme J.

J Leukoc Biol. 2004 May;75(5):777-84. Epub 2004 Mar 2.


PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.

Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, Opdenakker G, Van Damme J, Laureys G.

Am J Pathol. 2003 Nov;163(5):2065-75.


Posttranslational processing of chemokines.

Proost P, Mahieu F, Schutyser E, Van Damme J.

Methods Mol Biol. 2004;239:27-44. No abstract available.


The CC chemokine CCL20 and its receptor CCR6.

Schutyser E, Struyf S, Van Damme J.

Cytokine Growth Factor Rev. 2003 Oct;14(5):409-26. Review.


The CXC chemokine GCP-2/CXCL6 is predominantly induced in mesenchymal cells by interleukin-1beta and is down-regulated by interferon-gamma: comparison with interleukin-8/CXCL8.

Wuyts A, Struyf S, Gijsbers K, Schutyser E, Put W, Conings R, Lenaerts JP, Geboes K, Opdenakker G, Menten P, Proost P, Van Damme J.

Lab Invest. 2003 Jan;83(1):23-34.


Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma.

Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J.

J Biol Chem. 2002 Jul 5;277(27):24584-93. Epub 2002 Apr 26.


Selective induction of CCL18/PARC by staphylococcal enterotoxins in mononuclear cells and enhanced levels in septic and rheumatoid arthritis.

Schutyser E, Struyf S, Wuyts A, Put W, Geboes K, Grillet B, Opdenakker G, Van Damme J.

Eur J Immunol. 2001 Dec;31(12):3755-62.


Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.

Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J.

Blood. 2001 Dec 15;98(13):3554-61.


Gene cloning of a new plasma CC chemokine, activating and attracting myeloid cells in synergy with other chemoattractants.

Struyf S, Stoops G, Van Coillie E, Gouwy M, Schutyser E, Lenaerts JP, Fiten P, Van Aelst I, Proost P, Opdenakker G, Van Damme J.

Biochemistry. 2001 Oct 2;40(39):11715-22.


Biochemical and biological characterization of neutrophil chemotactic protein, a novel rabbit CXC chemokine from alveolar macrophages.

Wuyts A, Schutyser E, Menten P, Struyf S, D'Haese A, Bult H, Opdenakker G, Proost P, Van Damme J.

Biochemistry. 2000 Nov 28;39(47):14549-57.


Regulated production and molecular diversity of human liver and activation-regulated chemokine/macrophage inflammatory protein-3 alpha from normal and transformed cells.

Schutyser E, Struyf S, Menten P, Lenaerts JP, Conings R, Put W, Wuyts A, Proost P, Van Damme J.

J Immunol. 2000 Oct 15;165(8):4470-7.


Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist.

Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J.

Blood. 2000 Sep 1;96(5):1674-80.


The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.

Menten P, Struyf S, Schutyser E, Wuyts A, De Clercq E, Schols D, Proost P, Van Damme J.

J Clin Invest. 1999 Aug;104(4):R1-5.

Supplemental Content

Loading ...
Support Center